Georgetown University Medical Center today announces the launch of a phase II clinical trial to study the safety of the cancer drug nilotinib and its effects on clinical outcomes and biomarkers in people with Parkinson’s disease.
from Dementia Big http://ift.tt/2lWawer via alcoholic dementia
http://ift.tt/2mByVTq
No comments:
Post a Comment